Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Rex Ying is an Assistant Professor in the Department of Computer Science at Yale University's School of Engineering & Applied Science. He leads research in graph neural networks, geometric representation learning, and explainable AI, with applications spanning physical simulations, biology, knowledge graphs, and recommender systems. His lab actively recruits PhD students interested in geometric deep learning, graph neural networks, and trustworthy AI. Dr. Ying received his PhD in Computer Science from Stanford University under Jure Leskovec, with a thesis titled "Towards Expressive and Scalable Deep Representation Learning for Graphs." Prior to that, he graduated from Duke University in 2016 with highest distinction, majoring in Computer Science and Mathematics. His research focuses on three interconnected areas: advancing graph neural network architectures for improved expressiveness, scalability, and interpretability; innovating in geometric representation learning for data with diverse characteristics; and developing real-world applications across scientific domains. He has pioneered influential algorithms including GraphSAGE, PinSAGE, and GNNExplainer, and developed the first billion-scale graph embedding services at Pinterest as well as graph-based anomaly detection algorithms at Amazon. His recent publication trends show a strong focus on hyperbolic geometry for foundation models, non-Euclidean representation learning, and multimodal applications in computational biology. The research demonstrates increasing integration of geometric deep learning with large language models and foundation model architectures. KDD 2022 Dissertation Award 2019 Baidu Scholarship in Artificial Intelligence Dr. Ying actively serves the research community as a committee member for major conferences including AAAI, ICML, NeurIPS, ICLR, KDD, and WebConf for over seven years, and as area chair for LoG 2022. He co-leads the open-source PyTorch Geometric project and has organized numerous workshops on graph learning. His industry collaborations include Pinterest, Amazon, Facebook AI Research, DeepMind, Siemens, SLAC National Accelerator Laboratory, and Saudi Aramco. He teaches "Deep Learning for Graph-Structured Data" at Yale and mentors students in developing cutting-edge graph learning algorithms. His research lab collaborates with both academic institutions and industry partners to advance the state-of-the-art in graph representation learning, with particular emphasis on geometric deep learning and its applications to scientific discovery and real-world systems.
Karl Griswold is a Professor of Engineering at Dartmouth College's Thayer School of Engineering, where he leads the Griswold Research Group focused on protein engineering and biotherapeutics development. His interdisciplinary work spans chemical, biological, and engineering disciplines to address critical challenges in drug-resistant infections and protein therapeutics. Education: BS in Chemistry from Southwest Texas State University (1995) PhD in Chemistry from the University of Texas at Austin (2005) Research Focus: Professor Griswold's laboratory specializes in protein engineering, directed evolution, and biotherapeutics development , creating novel biomolecules with superior functionality compared to natural proteins. The group develops high-throughput screening methods, protein deimmunization strategies, enhanced expression systems, and antibacterial agents targeting drug-resistant infections. Their work has significant translational potential for treating conditions like MRSA and Pseudomonas aeruginosa infections. Scientific Recognition: Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008) NIH Biotechnology Training Grant (2000-2003) Royston M. Roberts - Regents Fellowship, University of Texas (1999) DOW Chemical Foundation Scholar, Texas State University (1991-1995) Senior Fellow, National Academy of Inventors Research Leadership: As co-founder and CEO of Stealth Biologics, Professor Griswold translates academic research into commercial applications. His work has secured NIH funding and Dartmouth Innovations Accelerator support, with research featured in Chemical & Engineering News, Vermont Public Radio, and the New Hampshire Union Leader for developing alternatives to traditional antibiotics. Research Environment: The Griswold Research Group maintains extensive collaborations across disciplines including clinical medicine, immunology, structural biology, and chemical engineering. This interdisciplinary approach prepares trainees for careers at the intersection of multiple scientific fields, with research focusing on Biomolecular Antimicrobial Therapies, Deimmunizing Protein Therapeutics, and Gene Library Construction Technologies.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Pengyu Chen is Francis Family Associate Professor and Ginn Faculty Achievement Fellow in Materials Engineering at Auburn University. His NIH-funded research develops nanoplasmonic biosensors for rapid disease diagnosis and immune monitoring, with applications in precision medicine and cancer immunotherapy. Research focuses on: Rapid diagnostic technologies for COVID-19 and other diseases Single-cell analysis platforms Nanoparticle-based cancer therapies Food/environmental safety monitoring Recent publications demonstrate innovations in nanoplasmonic sensing, targeted drug delivery, 3D-printed implants, and tumor microenvironment analysis. His work integrates nanotechnology, immunology, and microfluidics for biomedical applications.
Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.
Michel Versluis is a Full Professor at the University of Twente, Netherlands, specializing in Physical and Medical Acoustics within the Physics of Fluids group. His work focuses on microbubbles and microdroplets for medical imaging and therapy, as well as microfluidic applications in medicine and nanotechnology. University of Twente, Physics of Fluids group His research bridges physics and biomedical engineering, with publications in high-impact journals like PNAS and IEEE Transactions. Recent work emphasizes ultrasound-driven microbubble dynamics, additive manufacturing of flow phantoms, and deep learning for super-resolution imaging. 2025 publications: vascular phantoms, PROTEUS simulator, acoustic microbubble control 2024 innovations: 3D-printed medical devices, immunogenic cell death optimization Contact: m.versluis@utwente.nl
Dr. Xi Chen is a Professor in the Department of Chemistry at the University of California, Davis, where he has been a faculty member since 2003. His research spans carbohydrate chemistry, glycobiology, and cancer biology, with notable contributions to chemoenzymatic methods for glycoconjugate synthesis. Dr. Chen's work focuses on developing hybrid chemical-enzymatic approaches to synthesize complex carbohydrates and glycoconjugates, characterizing glycosyltransferase mechanisms, and designing enzyme mutants for improved catalysis. He also investigates carbohydrate-based diagnostics and therapeutics, particularly in cancer and inflammatory diseases. His recent publications highlight interdisciplinary studies linking carbohydrate metabolism to p53 tumor suppression pathways and RNA-binding protein regulation in cancer. Awards include AAAS Fellow (2015), ACS Isbell Award (2012), and NSF CAREER Award (2006). He earned his Ph.D. at Wayne State University (2000) and B.S. at Xiamen University (1994). Scientific Awards American Association for the Advancement of Science Fellow (2015) Dean's Team Award for Excellence (2013) Carbohydrate Research Award for Creativity (2013) ACS CARB Horace S. Isbell Award (2012)
Michael Krisinger is an Associate Professor of Teaching in the Department of Biochemistry & Molecular Biology at the University of British Columbia . He began his teaching career in 2010, transitioning to full-time in 2013. He lectures Biochemistry 202 (Introductory Medical Biochemistry) and Biochemistry 303 (Molecular Biochemistry) while serving as a tutor in the Faculty of Medicine's Case Based Learning program. Krisinger co-developed the department's two-course summer program for international students and mentors postdoctoral fellows in teaching. He also manages the department's CANVAS digital learning platform. Krisinger's research focuses on the molecular mechanisms of coagulation and complement system regulation , particularly their evolutionary relationship and functional interplay. His work has explored thrombin's role in complement activation, polyphosphate-mediated complement suppression, and nanoparticle surface interactions with proteolytic cascades. He previously co-supervised graduate students at UBC's Centre for Blood Research before prioritizing education. Publications highlight his expertise in protease-substrate dynamics , lipoprotein-phospholipid interactions , and hemostasis-immunity crosstalk . He remains engaged in public science through community environmental initiatives and local outreach activities.
Cecilia Leal is a Professor and Racheff Faculty Scholar in the Department of Materials Science and Engineering at the University of Illinois at Urbana-Champaign, with additional appointments at the Carle Illinois College of Medicine, Materials Research Laboratory, and Beckman Institute. Her interdisciplinary research program bridges materials science, biophysics, and medicine to develop innovative therapeutic delivery systems. Dr. Leal's research focuses on the self-organization of biomolecular systems, particularly lipid membranes, peptides, and nucleic acids. Her lab investigates how structural complexity of lipids and bio-membranes relates to disease mechanisms and informs the design of better gene and drug delivery systems. Key projects include developing lipid nanoparticles for mRNA delivery, studying polymer-lipid hybrid membranes, and characterizing lipid droplet dynamics in metabolic diseases. The lab employs advanced techniques including Small Angle X-ray Scattering, Cryo-EM, and live cell imaging. Her recent publications (2023-2025) reveal a strong emphasis on lipid-based delivery systems for mRNA therapeutics and cancer treatment, with particular attention to how nanostructure affects delivery efficiency. The research spans from fundamental biophysics of lipid-polymer interactions to applied therapeutic development, demonstrating consistent translation of basic science to medical applications. University of Illinois Provost's Distinguished Promotion to Full Professor Award (2024) University of Illinois Scholar (2023) NIH New Innovator Award (2016) NSF CAREER Award (2016) Racheff Faculty Scholar Award (2019) Dr. Leal has mentored numerous graduate students and postdocs, many now in prominent positions at MIT, Stanford, Dow Chemical, and pharmaceutical companies. Her research is supported by multiple NIH and NSF grants, and she maintains active collaborations with medical researchers studying obesity, cancer, and respiratory diseases. She teaches core courses including MSE 201 (Phases and Phase Relations) and MSE 473 (Biomolecular Materials Science), consistently earning excellent teaching ratings. The Leal Lab operates as an interdisciplinary team of materials scientists, physicists, and chemists using cutting-edge characterization tools to solve biomedical challenges. The lab's work on lipid nanoparticle structure has direct relevance to next-generation mRNA vaccines and cancer therapies, with several publications highlighted in C&EN News and other prominent scientific media.
Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.
Prof. Dr. Ralph Bock serves as Director of Department 3: Organelle Biology, Biotechnology and Molecular Ecophysiology at the Max Planck Institute of Molecular Plant Physiology in Potsdam, Germany, where he also leads the Organelle Biology and Biotechnology research group. Previously, he held positions as C4 Professor for Plant Biochemistry and Biotechnology at the University of Münster (2001-2004) and Group Leader at the Institute of Biology III, University of Freiburg (1996-2001). His academic credentials include: Habilitation: University of Freiburg, 1999 Doctorate: University of Freiburg, 1996 Diploma: University of Halle, 1993 Prof. Bock's research focuses on plant molecular biology with particular emphasis on chloroplast biology, organelle biotechnology, and molecular ecophysiology. His work spans genetic engineering of plastids, photosynthesis research, plant biotechnology applications, and understanding organelle-nucleus communication. He has made significant contributions to developing chloroplast transformation systems and applying them to molecular farming, metabolic engineering, and understanding fundamental processes in plant cell biology. His research has important implications for sustainable agriculture, bioenergy, and pharmaceutical production, particularly through the development of plant-based systems for producing vaccines and therapeutic proteins. Analysis of Prof. Bock's recent publications (2023-2025) reveals a strong focus on chloroplast biology, genetic engineering, and molecular farming applications. His work spans fundamental research on organelle genetics, photosynthesis, and stress responses, as well as applied research on using plant and algal systems for biopharmaceutical production. A notable trend is the increasing use of advanced genetic engineering techniques, including CRISPR-based approaches, to manipulate organelle genomes. His research also shows growing interest in algal systems as alternative expression platforms for molecular farming, particularly red algae like Porphyridium for producing viral antigens and glycoproteins.
Adam Caparco is the DiPietro Assistant Professor of Chemical Engineering at Northeastern University, with a 25% joint appointment in the Department of Chemistry and Chemical Biology. He leads the Caparco Research Group, focusing on agricultural and environmental biotechnology, enzyme immobilization, and protein assemblies. His work integrates plant virology, nanotechnology, and molecular engineering to address sustainability challenges in agriculture and environmental remediation. He is a member of the Institute for Plant-Human Interface and holds affiliations with Northeastern’s College of Engineering and School of Arts and Sciences. Education: B.S. in Chemical and Biomolecular Engineering from UCLA (2015), Ph.D. from Georgia Tech (2020) under Julie Champion and Andreas Bommarius, followed by a USDA NIFA Postdoctoral Fellowship at UC San Diego under Nicole Steinmetz. His research spans plant immunoengineering, biomanufacturing in plants, and protein-based nanomaterials for bioremediation. Research Interests Plant excretion pathways for pathogen defense and environmental remediation Design of immobilized enzymes for green chemical synthesis Plant virus nanoparticles for nucleic acid delivery and immunity modulation Multifunctional protein engineering for sustainable agriculture Recent articles highlight advancements in plant virus-based delivery systems, enzyme immobilization strategies, and nano-enabled precision agriculture. Awards include the USDA NIFA Postdoctoral Fellowship. Caparco advises graduate and undergraduate researchers, including Julia Hilgemberg Merlin (PhD ChE), Olha Bereziuk (PhD CCB), and Paul Carter (PhD ChE). He collaborates widely and seeks to expand interdisciplinary research in plant biotechnology. Labs/Teams: Caparco Research Group (EXP 420 lab, EXP 530B office) and the Institute for Plant-Human Interface.
